# Chronic Obstructive Pulmonary Disease (COPD) Management

## Diagnosis
- Post-bronchodilator FEV1/FVC <0.70 confirms airflow obstruction
- Symptoms: Dyspnea, chronic cough, sputum production
- Risk factors: Smoking (>10 pack-years), occupational exposures, alpha-1 antitrypsin deficiency

## GOLD Severity Classification (by FEV1 % predicted)
- **GOLD 1 (Mild)**: FEV1 ≥80%
- **GOLD 2 (Moderate)**: 50% ≤ FEV1 < 80%
- **GOLD 3 (Severe)**: 30% ≤ FEV1 < 50%
- **GOLD 4 (Very Severe)**: FEV1 <30%

## GOLD ABE Assessment (symptom burden + exacerbation history)
- **Group A**: Low symptoms (mMRC 0-1 or CAT <10), 0-1 moderate exacerbations
- **Group B**: High symptoms (mMRC ≥2 or CAT ≥10), 0-1 moderate exacerbations
- **Group E**: ≥2 moderate exacerbations or ≥1 hospitalization regardless of symptoms

## Pharmacotherapy
### Group A
- Bronchodilator (SABA or SAMA as needed, or LABA or LAMA)

### Group B
- LABA + LAMA combination preferred

### Group E
- LABA + LAMA preferred initial therapy
- If eosinophils ≥300: LABA + LAMA + ICS (triple therapy)
- If eosinophils 100-300: Consider ICS addition
- If eosinophils <100: Avoid ICS

## Key Medications
- **LAMA**: Tiotropium, umeclidinium, glycopyrrolate
- **LABA**: Salmeterol, formoterol, indacaterol, olodaterol, vilanterol
- **ICS**: Fluticasone, budesonide, beclomethasone (only with LABA in COPD)
- **PDE4 inhibitor**: Roflumilast — for FEV1 <50%, chronic bronchitis phenotype, frequent exacerbations

## Acute Exacerbation Management (AECOPD)
- **Bronchodilators**: Increase frequency of SABA ± SAMA
- **Systemic corticosteroids**: Prednisone 40mg × 5 days
- **Antibiotics**: If increased sputum purulence + either increased dyspnea or sputum volume; amoxicillin-clavulanate, azithromycin, or doxycycline
- **Oxygen**: Target SpO2 88-92% (avoid over-oxygenation)
- **NIV (BiPAP)**: For respiratory acidosis (pH <7.35), severe dyspnea

## Non-Pharmacologic
- **Smoking cessation**: Single most effective intervention
- **Vaccination**: Influenza (annual), pneumococcal (PCV20), COVID-19, Tdap, Zoster
- **Pulmonary rehabilitation**: Reduces dyspnea, improves exercise tolerance and quality of life
- **Long-term oxygen**: If PaO2 ≤55 mmHg or SpO2 ≤88% at rest

## Surgical Options
- Lung volume reduction surgery (LVRS) for upper-lobe predominant emphysema
- Lung transplantation for advanced disease
